PREVAIL is a study enrolling people around the world who have immunoglobulin A nephropathy, also known as IgAN. Kidney damage from IgAN can lead to protein and blood leaking into the urine (proteinuria).
The main goal of PREVAIL is to learn about the effects of a study drug called felzartamab on proteinuria in adults with IgAN. Participants will be randomly assigned to receive either felzartamab or placebo for over 20 weeks.
